VS-5584 (SB2343)MTOR/P13K inhibitor,potent and selective CAS# 1246560-33-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1246560-33-7 | SDF | Download SDF |
PubChem ID | 46912230 | Appearance | Powder |
Formula | C17H22N8O | M.Wt | 354.41 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | SB2343 | ||
Solubility | DMSO : 33.33 mg/mL (94.04 mM; Need ultrasonic) | ||
Chemical Name | 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine | ||
SMILES | CC1=NC2=C(N=C(N=C2N1C(C)C)N3CCOCC3)C4=CN=C(N=C4)N | ||
Standard InChIKey | QYBGBLQCOOISAR-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H22N8O/c1-10(2)25-11(3)21-14-13(12-8-19-16(18)20-9-12)22-17(23-15(14)25)24-4-6-26-7-5-24/h8-10H,4-7H2,1-3H3,(H2,18,19,20) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | VS-5584 (SB2343) is a potent and selective dual inhibitor of PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively. | |||||
Targets | mTOR | PI3Kα | PI3Kα-H1047 | PI3Kβ | PI3Kδ | PI3Kγ |
IC50 | 3.4 nM | 2.6 nM | 3.3 nM | 21 nM | 2.7 nM | 3.0 nM |
VS-5584 (SB2343) Dilution Calculator
VS-5584 (SB2343) Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.8216 mL | 14.108 mL | 28.2159 mL | 56.4318 mL | 70.5398 mL |
5 mM | 0.5643 mL | 2.8216 mL | 5.6432 mL | 11.2864 mL | 14.108 mL |
10 mM | 0.2822 mL | 1.4108 mL | 2.8216 mL | 5.6432 mL | 7.054 mL |
50 mM | 0.0564 mL | 0.2822 mL | 0.5643 mL | 1.1286 mL | 1.4108 mL |
100 mM | 0.0282 mL | 0.1411 mL | 0.2822 mL | 0.5643 mL | 0.7054 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
VS-5584 (SB2343), a purine analog, is a novel small-molecule inhibitor of both mammalian target of rapamycin (mTOR) kinase and all class I phosphoinostide 3-kinase (PI3K) isoforms that ATP-competitively inhibits the activity of mTOR, PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ with values of 50% inhibition concentration IC50 of 37 nmol/L, 16 nmol/L, 68 nmol/L, 25 nmol/L and 42 nmol/L respectively. VS-5585 robustly modulates the cellular PI3K/mTOR pathway, one of the most commonly activated signaling pathways in human cancer, through inhibition of phosphorylation of substrates downstream of PI3K and mTORC1/2. Moreover, VS-5584 has been found to dose-dependently inhibit PI3K/mTOR signaling in tumor tissue resulting in tumor growth inhibition in human xengograft models.
Reference
Hart S, Novotny-Diermayr V, Goh KC, Williams M, Tan YC, Ong LC, Cheong A, Ng BK, Amalini C, Madan B, Nagaraj H, Jayaraman R, Pasha KM, Ethirajulu K, Chng WJ, Mustafa N, Goh BC, Benes C, McDermott U, Garnett M, Dymock B, Wood JM. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther. 2013 Feb;12(2):151-61. doi: 10.1158/1535-7163.MCT-12-0466. Epub 2012 Dec 27.
- MPI-0479605
Catalog No.:BCC5347
CAS No.:1246529-32-7
- SR1078
Catalog No.:BCC1963
CAS No.:1246525-60-9
- (-)-Dihydroguaiaretic acid
Catalog No.:BCN8002
CAS No.:124649-78-1
- Officinaruminane B
Catalog No.:BCN3594
CAS No.:1246282-67-6
- C3bot (154-182)
Catalog No.:BCC6117
CAS No.:1246280-79-4
- VU 0364439
Catalog No.:BCC1239
CAS No.:1246086-78-1
- Methyl (2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenylpropionate
Catalog No.:BCN8363
CAS No.:124605-42-1
- 4'-O-trans-p-Coumaroylmussaenoside
Catalog No.:BCN6130
CAS No.:1246012-27-0
- 6-O-trans-p-Coumaroylshanzhiside methyl ester
Catalog No.:BCN1597
CAS No.:1246012-26-9
- 6-O-trans-Cinnamoylphlorigidoside B
Catalog No.:BCN6129
CAS No.:1246012-25-8
- 6-O-Benzoylphlorigidoside B
Catalog No.:BCN6128
CAS No.:1246012-24-7
- 2-Methyl-4-(2-methylbutyryl)phloroglucinol
Catalog No.:BCN7175
CAS No.:124598-11-4
- 5,7,4'-Trihydroxy-3,6-dimethoxy-3',5'-diprenylflavone
Catalog No.:BCN1596
CAS No.:1246926-08-8
- 5'-Prenylaliarin
Catalog No.:BCN4829
CAS No.:1246926-09-9
- Methyl-Dodovisate A
Catalog No.:BCN4719
CAS No.:1246937-33-6
- Meprednisone
Catalog No.:BCC4893
CAS No.:1247-42-3
- Quinovic acid 3-O-(6-deoxy-beta-D-glucopyranoside) 28-O-beta-D-glucopyranosyl ester
Catalog No.:BCN1595
CAS No.:124727-10-2
- Losartan Potassium (DuP 753)
Catalog No.:BCC1080
CAS No.:124750-99-8
- P 22077
Catalog No.:BCC3616
CAS No.:1247819-59-5
- USP7-USP47 inhibitor
Catalog No.:BCC4113
CAS No.:1247825-37-1
- Valaciclovir
Catalog No.:BCC2025
CAS No.:124832-26-4
- Valacyclovir hydrochloride
Catalog No.:BCC4051
CAS No.:124832-27-5
- Nadifloxacin
Catalog No.:BCC4804
CAS No.:124858-35-1
- 5-Dehydroxyparatocarpin K
Catalog No.:BCN4017
CAS No.:124858-37-3
Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.[Pubmed:25317974]
J Chem Inf Model. 2014 Nov 24;54(11):3238-50.
Phosphoinositide 3-kinases (PI3Ks) and the mammalian target of rapamycin (mTOR) act as critical effectors in a commonly deregulated cell signaling pathway in human cancers. The abnormal activation of the PI3K/mTOR pathway has been shown to play a role in initiation, progression, and metastasis of human tumors. Being one of the most frequently activated pathways in cancer, much effort has been directed toward inhibition of the PI3K/mTOR pathway as a novel oncology therapy. Previous work by a number of groups has revealed several selective PI3K and dual mTOR/PI3K inhibitors. However, there are few reports of therapeutic agents with a pan-PI3K/mTOR inhibitory profile within a narrow concentration range. We therefore initiated a drug discovery project with the aim of discovering dual mTOR/PI3K inhibitors which would equipotently inhibit the 4 isoforms of PI3K, alpha, beta, gamma, and delta, and mTOR a compelling profile for powerful blockage of the PI3K/mTOR pathway. A pharmacophore model was generated and used for designing a series of novel compounds, based on a purine scaffold, which potently inhibited mTOR and PI3Ks. These compounds contained a phenol headgroup essential for binding to the target proteins. Early efforts concentrated on finding replacements for the phenol as it was rapidly conjugated resulting in a short half-life in vivo. Compounds with a variety of headgroups were docked into the PI3Kalpha and mTOR ATP-binding sites, and aminopyrimidine and aminopyrazine were found to make excellent phenol replacements. Further structure guided optimization of side chains in the 8- and 9-positions of the purine resulted in potent inhibitors with good PKDM properties. As the PI3 kinases play a role in insulin signaling, it is believed that targeting mTOR selectively may give the benefit of blocking the AKT-pathway while avoiding the potential side effects associated with PI3K inhibition. As a result we designed a further series of selective mTOR kinase inhibitors. The project was successfully concluded by progressing both a dual mTOR/PI3K inhibitor, SB2343, and a selective mTOR inhibitor, SB2602, into preclinical development. SB2343 has since entered phase 1 clinical development as VS-5584.